A to Z / Repair & recovery

KPV

Also known as lysine-proline-valine, alpha-MSH(11-13).

Best known for The gut and inflammation peptide with a rising profile

Evidence★☆☆☆☆

Safety dataLargely unknown

Route Oral · injectable · topical

United StatesNot approved; PCAC recommended Jul 2026 (8-6, one abstention)

AustraliaNot listed by name; unapproved therapeutic good

as at 16 September 2026

What it is

KPV is a tripeptide (just three amino acids, lysine-proline-valine) and the smallest active fragment of alpha-melanocyte stimulating hormone. It is the anti-inflammatory tail of that hormone, without the pigmentation activity. KPV is at the animal research stage, with no human trials yet. It is not approved, and in July 2026 an FDA advisory committee recommended it for compounding eligibility.

What the full entry covers

The book carries the rest of this entry:

Where the research stands, with every claim cited
What people commonly ask, and what the research shows so far
Dosing in four labelled bands, described and not recommended
Side effects, serious risks, cautions and interactions
Questions to discuss with your doctor
How it compares with BPC-157, Larazotide, LL-37, VIP

Related entries

BPC-157Tendon, joint and gut repair · Evidence ★★☆☆☆
LarazotideThe "leaky gut" peptide that reached phase 3 · Evidence ★★★☆☆
LL-37The body's own antimicrobial peptide, discussed for chronic infection · Evidence ★☆☆☆☆
VIPThe CIRS and mould-illness peptide · Evidence ★★☆☆☆

A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.

This page describes what is known and not known about KPV. It is not medical advice and not a recommendation to use it.